Walleye Capital
MTCR

Walleye Capital’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Walleye Capital’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,787
Closed -$45 – 1918
2021
Q2 		$45 Buy
+11,787
New +$48.7K ﹤0.01% 1236

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's MTCR Position: Q3 2021 in Review

Walleye Capital sold out of Metacrine, Inc. Common Stock (MTCR) in Q3 2021, closing a stake of 11,787 shares — an estimated $45 sold.

Walleye Capital first reported a position in MTCR in Q2 2021 and held it in 1 quarter. The position peaked at $45 in Q2 2021. 35 funds tracked by Wall St. Rank hold MTCR as of Q3 2021.

  • Walleye Capital reported no remaining Metacrine, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Walleye Capital sold 11,787 Metacrine, Inc. Common Stock shares in Q3 2021, an estimated $45.
  • Walleye Capital first reported a position in Metacrine, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Walleye Capital's Metacrine, Inc. Common Stock position peaked at $45 in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q3 2021.

Based on Walleye Capital's 13F filing for Q3 2021, filed 15 Nov 2021.